

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :**A61K 9/127, 38/19****A1**

(11) International Publication Number:

WO 96/29989

(43) International Publication Date:

3 October 1996 (03.10.96)

(21) International Application Number:

PCT/US96/04261

(22) International Filing Date:

28 March 1996 (28.03.96)

(30) Priority Data:

08/414,161**31 March 1995 (31.03.95)****US**(71) Applicant: **AMGEN INC. [US/US]; Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, CA 91320-1789 (US).**(72) Inventors: **COLLINS, David; 127 McAfee, Thousand Oaks, CA 91360 (US). CHA, Younsik; 1267 Calle Olmo, Thousand Oaks, CA 91360 (US). BREMS, David; 3778 Calle Clara Vista, Newbury Park, CA 91320 (US).**(74) Agents: **ODRE, Steven, M. et al.; Amgen Inc., Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, CA 91320-1789 (US).**(81) Designated States: **AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).****Published***With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*(54) Title: **STABLE PROTEIN:PHOSPHOLIPID COMPOSITIONS AND METHODS**

(57) Abstract

The invention relates to stable compositions of proteins and related methods wherein a protein capable of transitioning into the molten globular state is contacted with a negatively charged lipid vesicle, thereby stabilizing the protein against thermally-induced aggregation, denaturation, and loss of activity. The protein:phospholipid complex directly stabilizes the secondary and tertiary structure of the protein, and the compositions are useful in high temperature formulations and in novel delivery vehicles.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

-1-

STABLE PROTEIN:PHOSPHOLIPID COMPOSITIONS AND METHODS

BACKGROUND OF THE INVENTION

5

The present invention relates to protein:phospholipid structures which are useful for stabilizing the secondary and tertiary structure of proteins capable of transitioning into the molten
10 globular state. More particularly, this invention relates to G-CSF:phospholipid and MGDF:phospholipid compositions having increased stability, exhibiting increased shelf life, and capable of use in high temperature formulations and as novel delivery vehicles.

15 Several proteins have been shown to transition into a molten globular state (MGS). Van der Goot, F.G., *Nature* 354, 408-410 (1991). Proteins in the molten globular state exhibit secondary structure which is comparable to the native protein yet they lack rigid
20 tertiary structure. Pitsyn et al., *FEBS Letters* 262:1, 20-24 (1990). In some cases, transition into this state is accompanied by exposure of previously hidden hydrophobic regions of the protein. By exposing critical hydrophobic residues, the MGS may be an
25 intermediate in the aggregation and precipitation of proteins. The MGS conformation can be detected by comparing the circular dichroism in the far UV region with the spectra of aromatic side chains (near UV circular dichroism and fluorescence). The molten
30 globular state exhibits aromatic group spectral changes in the absence of far UV circular dichroism changes; Bychkova et al., *FEBS Letters* 238: 231-234 (1988), and may be involved in membrane penetration by some proteins Bychkova et al., *FEBS Letters* 238: 231-234 (1988); Van
35 der Goot, F.G., *Nature* 354, 408-410 (1991).

Granulocyte colony stimulating factor (G-CSF)

-2-

is one protein known to transition into the MGS prior to aggregation. Human recombinant G-CSF selectively stimulates neutrophils, a type of white blood cell used for fighting infection. Currently, Filgrastim, a recombinant G-CSF, is available for therapeutic use. The structure of G-CSF under various conditions has been extensively studied; Lu et al., *J. Biol. Chem.* Vol. 267, 8770-8777 (1992). Because of its hydrophobic characteristics, G-CSF is difficult to formulate for extended shelf life. Formulations of certain hydrophobic proteins lose activity due to formation of dimer and higher order aggregates (macro range) during long-term storage. Other chemical changes, such as deamidation and oxidation may also occur upon storage. In addition, the G-CSF formulator must protect against denaturation and, in particular, look to maintain the stability of the secondary and tertiary structure of the protein.

Human GM-CSF is a 22-kDa glycoprotein required continuously for the *in vitro* proliferation of macrophage and granulocytic progenitor cells. It also controls the irreversible commitment of these progenitors to form granulocytes and macrophages. Other biological activities may include regulation of the functional activity of mature cell types; Gough et al., *Nature*, 309, 763-767 (1984), and increasing chemotaxis towards recognized chemoattractants; Williams et al., *Hematology*, 4th ed. (1990). GM-CSF also stimulates the production of monocytes, and thus may be useful in the treatment of monocytic disorders, such as monocytopenia.

Human GM-CSF can be obtained and purified from a number of sources. Procedures for the production of recombinant human GM-CSF have been previously described by Burgess et al., *Blood*, 69:1, 43-51 (1987). U.S. Patent 5,047,504 (Boone), incorporated herein by reference, has enabled the production of commercial

-3-

scale quantities of GM-CSF in non-glycosylated form as a product of procaryotic host cell expression.

MGDF, or megakaryocyte growth and differentiation factor, is a recently cloned cytokine that appears to be the major regulator of circulating platelet levels. See Bartley, T.D. et al., *Cell* 77:1117-1124 (1994); Lok, S. et al., *Nature* 369:565-568 (1994); de Sauvage, F.J. et al., *Nature* 369:533-538 (1994); Miyazake, H. et al., *Exp. Hematol.* 22:838 (1994); and Kuter, D.J. et al., *PNAS USA*, 91:11104-11108 (1994). MGDF is also referred to as thrombopoietin (TPO), mpl-ligand, and megapoietin. Mature human MGDF is a protein having 332 amino acids in total. The sequence of this protein and the corresponding cDNA are shown in FIGURE 29 herein.

Recombinant MGDF produced in both Chinese Hamster Ovary (CHO) and *E. coli* cells has been demonstrated to have a biological activity of specifically stimulating or increasing megakaryocytes and/or platelets *in vivo* in mice, rats and monkeys. See e.g., Hunt, P. et al., *Blood* 84(10):390A (1994). Human MGDF molecules that have been truncated so that they extend at least 151 amino acids, starting from amino acid position 1 in FIGURE 29, retain biological activity *in vivo*. It is also possible to remove up to the first six amino acids at the N-terminus of the human sequence MGDF protein and retain biological activity. Therefore, it appears that biological activity is retained within amino acids 7 to 151 (inclusive) of the mature amino acid sequence of human MGDF shown in FIGURE 29.

Naturally occurring MGDF is a glycosylated molecule. The glycosylation pattern of natural MGDF is related to two key domains that have been found in MGDF. The sequence of the first approximately 151 amino acids of human MGDF, corresponding to an active portion of the molecule, bears notable homology to erythropoietin

-4-

(EPO), a cytokine capable of stimulating production of erythrocytes, and is referred to as the "EPO-like" domain of human MGDF. The remaining amino acids of the mature protein make up a so-called "N-linked carbohydrate" domain, since they include most if not all of the sites for N-linked glycosylation. In human MGDF, there are six N-linked glycosylation sites all contained in the N-linked glycosylation domain. Both domains contain O-linked glycosylation sites. There are an estimated 12-14 O-linked glycosylation chains in the molecule. Experimental evidence with human MGDF DNA expressed recombinantly in CHO cells reveals that in the EPO-like domain at least two O-linked sites are glycosylated, at positions 1 (Ser) and 37 (Thr).

While proteins such as G-CSF and MGDF may be stabilized under certain defined conditions, there still exists a need to extend the shelf life of these and other proteins by stabilizing the secondary and tertiary structure of the proteins. One way which has been tried in the past to work with such proteins is the use of liposomes. Liposomes are completely closed lipid bilayer membranes formed by water-insoluble polar lipids, particularly phospholipids. Liposome vesicles may have a single membrane bilayer (unilamellar) or may have multiple membrane bilayers (multilamellar). The bilayer is composed of two lipid monolayers having a hydrophilic (polar) "head" region and a hydrophobic (nonpolar) "tail" region wherein the hydrophobic tails orient toward the center of the bilayer, whereas the hydrophilic heads orient toward the aqueous phase. The stability, rigidity, and permeability of liposomes can be altered by changes in the phospholipid composition, by changes in temperature, by inclusion of a sterol or by incorporation of a charged amphiphile. The basic structure of liposomes may be made by a variety of techniques known in the art.

-5-

In the process of their formation liposomes can entrap water solutes in the aqueous channels and release them at variable rates. Upon the discovery that liposomes can introduce enzymes into cells and alter their metabolism (Gregoriadis, *New Engl. J. Med.* 295, 704-710, 765-770 (1976)), liposomes were heralded as the answer to the quest for targeted drug delivery. As a result, there is a great deal of developmental research in the pharmaceutical industry involving use of liposomes as slow release depots for drugs, vitamins and proteins sequestered within the hydrophobic layers or hydrophobic core of the liposome.

Successful use of liposomes as drug-carriers has been limited because the researchers attempting such use have encountered several problems. For example, liposomes are known to act as powerful immunological adjuncts to entrapped antigens and caution must be exercised when enzymes or other proteins of xenogenic origin are entrapped in the liposomes. Also, the rate of diffusion of the drug is difficult to control. This is a function of the inherent instability of the liposomes and the presence of certain blood components which accelerate diffusion of certain drugs. In addition, by their nature, some substances are poorly entrapped in liposomes and therefore diffuse rapidly in circulation. Finally, there has been a problem targeting any cells or organ other than the liver or spleen. An excellent review of liposomes, substances which have been incorporated into liposomes, and the problems associated with use of liposomes as drug carriers is "Liposomes" by Gregory Gregoriaidis, found in *Drug Carriers in Biology and Medicine*, Chapter 14, 287-341 (Academic Press, N.Y., 1979).

While much has been reported concerning attempts to use liposomes as drug carriers, little has been disclosed concerning the use of liposomes for

-6-

purposes of increasing shelf life of therapeutic peptides or proteins by stabilizing the structure of the peptide and/or protein. In PCT/US90/05163, entitled, "Therapeutic Peptides and Proteins", Hostetler, et al. disclose use of empty liposomes as a pharmaceutically acceptable diluent to solubilize polypeptides and/or proteins in order to prevent accumulation of the polypeptides and/or proteins at an air/water interface, and to prevent adsorption of the polypeptides and/or proteins to container surfaces. Hostetler et al. disclose that negatively charged phospholipid may be added up to about 50 mole percent, and that phosphatidylcholine, a neutral phospholipid, is the preferred liposome. Hostetler et al. do not disclose a diluent shown to stabilize the structure of a polypeptide and/or protein.

In PCT/US91/07694, entitled, "Preparation and Characterization of Liposomal Formulations of Tumor Necrosis Factor", Hung et al., a lipophilic modified tumor necrosis factor (TNF) molecule in association with the surface or encapsulated within a liposome is described. The liposomal lipophilic TNF molecules are reported to have enhanced *in vivo* stability. Stability referred to a decrease or a decreased tendency of the TNF-liposome to leak TNF into the system *in vivo*. The preferred liposomes were neutral lipids. Hung et al. do not disclose a TNF composition wherein the excipients have a stabilizing effect on the structure of the protein.

Nothing can be drawn from the literature concerning contacting a protein, e.g. G-CSF or MGDF, with a negatively charged lipid vesicle thereby directly stabilizing the protein against thermally-induced aggregation, denaturation, loss of activity, and unfolding of the secondary structure. The need exists for such compositions which provide the benefit of being

-7-

- useful in formulation procedures requiring high temperatures (e.g. incorporation of G-CSF and/or MGDF into polymers) as well as being used as novel delivery vehicles (e.g. oral administration of pegylated G-CSF).
- 5 The present invention provides such compositions.

SUMMARY OF THE INVENTION

- The present invention is directed to the
- 10 addition of hydrophobic excipients, e.g. lyso-phospholipids or other liposomes, to a protein under molten globular state conditions will directly stabilize the secondary and tertiary structure of the protein, thereby protecting the protein against
- 15 thermally-induced aggregation, denaturation, and loss of activity. In particular, the invention is directed to stable G-CSF:phospholipid and MGDF:phospholipid compositions. Surprisingly, the preferred G-CSF:phospholipid and MDGF:phospholipid compositions
- 20 can be cycled several times between 10-95°C with full recovery of protein secondary structure upon cooling. The compositions are useful for formulation procedures requiring high temperatures, as well as for use as novel delivery vehicles. In addition, the compositions
- 25 exhibit a prolonged shelf-life as compared to protein alone, and the interaction of protein with phospholipid vesicle prevents adsorption of protein to glass vials.

- In a preferred embodiment, the protein:phospholipid complex comprises a negatively
- 30 charged liposome which is selected from dioleoylphosphatidylglycerol (DOPG), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), eggphosphatidylglycerol,
- 35 dioleoylphosphatidylethanolamine (DOPE), eggphosphatidylethanolamine, dioleoylphosphatidic acid

-8-

(DOPA), dimyristoylphosphatidic acid (DMPA),
dipalmitoylphosphatidic acid (DPPA),
dioleoylphosphatidylserine (DOPS),
dimyristoylphosphatidylserine (DMPS),
5 dipalmitoylphosphatidylserine (DPPS),
eggphosphatidylserine, lysophosphatidylglycerol,
lysophosphatidylethanolamine, lysophosphatidylserine.
DOPG, a negatively charged, unsaturated phospholipid is
especially preferred. The invention further comprises a
10 pH maintained in the range of 3.0 - 7.5, and a
lipid:protein ratio of at least 10:1.

Additional elements that provide preferred
embodiments of the invention include use of chemically
modified proteins in the protein:phospholipid complex as
15 well as use of one or more of the following: an
isotonicity adjusting agent; a buffering agent; and a pH
adjusting agent. As would be understood by a person
having knowledge of the art, the invention encompasses
stable protein:phospholipid compositions having various
20 combinations of these additional elements.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 depicts the fluorescence emission
25 spectrum of rhG-CSF in the presence (curve 1) and
absence (curve 2) of DOPG vesicles. The concentration
of the rhG-CSF was 0.2 mg/ml. The DOPG:rhG-CSF ratio
(curve 1) was 100:1 (mole:mole).

30 FIGURE 2 shows the effect of increasing
lipid:protein ratio on the rhG-CSF fluorescence. F_0 is
the initial fluorescence (no lipid) and F refers to the
fluorescence after addition of lipid to achieve the
indicated molar ratio of lipid:rhG-CSF. Figure 2(a)
35 shows F/F_0 (■) and maximum emission wavelengths (Δ) for
mixtures of DOPG:rhG-CSF. Figure 2(b) shows F/F_0 (■)

-9-

and maximum emission wavelengths (Δ) for mixtures of DOPC:rhG-CSF.

5 FIGURE 3 shows Stern-Volmer plots of the quenching of rhG-CSF fluorescence by KI in the absence (●) and presence (○) of DOPG vesicles. Quenching experiments were performed by adding aliquots of KI to rhG-CSF (0.2 mg/ml) and DOPG:rhG-CSF (100:1 molar).

10 FIGURE 4 depicts quenching of rhG-CSF tryptophan fluorescence upon addition of pyrene decanoic acid. The emission wavelength was 327 nm. The DOPG:rhG-CSF ratio was 100:1 (molar).

15 FIGURE 5 is a graph showing a comparison of F intensity changes for rhG-CSF in the absence and presence of various lipids. In each case, the lipid:protein ratio was 100:1 (molar).

20 FIGURE 6 is a graph showing a comparison of shifts in emission maximums for rhG-CSF in the absence and presence of various lipids. In each case, the lipid:protein ratio was 100:1 (molar).

25 FIGURE 7 shows the effect of DMPC (curve 2), DMPG (curve 3), and DMPA (curve 4) on the CD of rhG-CSF (curve 1). In each case, the lipid:protein ratio was 50:1 (molar) in water, pH 6.0.

30 FIGURE 8 shows the effect of increasing temperature on the CD of rhG-CSF (curve 1) or DOPG:rhG-CSF (140:1 molar) (curve 2). The rhG-CSF concentration was 80 μ g/ml in water, pH 6.0. The temperature was scanned from 10-90°C at a rate of
35 100°C/hour.

-10-

FIGURE 9 shows differential scanning calorimetry thermograms for rhG-CSF (curve 1) and DOPG:rhG-CSF (45:1 molar) (curve 2). The concentration of rhG-CSF in the samples was 1 mg/ml (pH 7.0 in water).
5 The scan rate was 90°C/hour.

FIGURE 10 shows the effect of temperature cycling on the CD of rhG-CSF (curve 1) and DOPG:rhG-CSF (140:1 molar) (curve 2). The samples were rapidly
10 heated to 95°C and cooled to 10°C as indicated by the arrows. The rhG-CSF concentration in the samples was 80 µg/ml, pH 6.0.

FIGURE 11 shows the effect of temperature
15 cycling on the CD of rhG-CSF (curve 1) and DMPG:rhG-CSF (150:1 molar) (curve 2). The samples were heated to 95°C and cooled to 10°C. The rhG-CSF concentration in the samples was 80 µg/ml, pH 6.0.

FIGURE 12 shows the effect of temperature
20 cycling on the CD of rhG-CSF (curve 1) and DPPG:rhG-CSF (150:1 molar) (curve 2). The samples were heated to 95°C and cooled to 10°C. The rhG-CSF concentration in the samples was 80 µg/ml, pH 6.0.

FIGURE 13 is a graph showing the ability of
25 various lipids to stabilize rhG-CSF during freeze-drying. The lipid:protein ratio was 100:1 in each case. Stability was based upon retention of *in vitro* activity in the bone marrow assay. rhG-CSF alone
30 does not survive the freeze-drying process so the control used is untreated rhG-CSF in the absence of lipid.

FIGURE 14 shows the effects of various lipids
35 on the *in vivo* activity of rhG-CSF. Activity (WBC count)

-11-

was measured after subcutaneous injection of hamsters. The rhG-CSF dose was 100 µg/kg with a 100:1 lipid:protein ratio.

5 FIGURE 15 shows the effects of various lipids on the *in vivo* activity of rhG-CSF. Activity (WBC count) was measured after subcutaneous injection of hamsters. The rhG-CSF dose was 100 µg/kg with a 50:1 lipid:protein ratio.

10 FIGURE 16 is a graph showing a comparison of F intensity changes for CHO-G-CSF in the absence and presence of DOPG at varying pH's. In each case, the lipid:protein ratio was 100:1 (molar).

15 FIGURE 17 is a graph showing a comparison of shifts in emission maximums for CHO-G-CSF in the absence and presence of DOPG at varying pH's. In each case, the lipid:protein ratio was 100:1 (molar).

20 FIGURE 18 shows the effect of temperature cycling on the CD of PEG-G-CSF (___) and DMPG:PEG-G-CSF (17:1 molar) (----). The samples were heated to 90°C and cooled to 10°C.

25 FIGURE 19 shows: (a) the effect of temperature cycling on the CD of GM-CSF in PBS, pH 7.0. GM-CSF at 10°C (___) is compared to GM-CSF which was heated to 90°C and then cooled to 10°C (---); (b) the effect of
30 temperature cycling on the CD of DPPG:PEG-G-CSF (17:1 molar). DPPG:GM-CSF at 10°C (___) is compared to DPPG:GM-CSF which was heated to 90°C and then cooled to 10°C (---).

35 FIGURE 20 shows: (a) the results of the total WBC response to intraduodenal infusion of rhG-CSF in the

-12-

absence and presence of DOPG. The rhG-CSF dose was 750 $\mu\text{g/kg}$ and the lipid:protein ratio was 100:1; (b) the results of the total WBC response to intraduodenal infusion of PEG-G-CSF in the absence and presence of DOPG. The PEG-G-CSF dose was 750 $\mu\text{g/kg}$ and the lipid:protein ratio was 100:1.

FIGURE 21 shows the effect of DOPG on serum levels of PEG-G-CSF after intraduodenal pump infusion. The PEG-G-CSF dose was 750 $\mu\text{g/kg}$ and the lipid:protein ratio was 100:1.

FIGURE 22 depicts the fluorescence emission spectrum of MGDF in the presence and absence of DMPG vesicles. The concentration of the MGDF was 0.1 mg/ml. The MGDF was *E. coli* derived MGDF 1-163. The DMPG:MGDF ratio was 100:1 (mole:mole).

FIGURE 23 shows the effect of increasing lipid:protein ratio on the MGDF fluorescence. The MGDF was *E. coli* derived MGDF 1-163. Maximum emission wavelengths for mixtures of DMPG:MGDF at pH 5.0 (-O-) and pH 7.0 (-●-) are depicted.

FIGURE 24 shows Stern-Volmer plots of the quenching of MGDF fluorescence by KI in the absence (O) and presence (●) of DMPG vesicles. The MGDF was *E. coli* derived MGDF 1-163. Quenching experiments were performed by adding aliquots of KI to MDGF (0.1 mg/ml) and DMPG:MGDF (100:1 molar).

FIGURE 25 shows the effect of temperature cycling on the CD of MGDF (O) and DMPG:MGDF (100:1 molar) (). The MGDF was *E. coli* derived MGDF 1-163. The % remaining helicity refers to the amount of CD

detected at 10°C after each cycle (one cycle = samples were rapidly heated to 95°C and cooled to 10°C).

FIGURE 26 shows the extent of MGDF (\pm DMPG) denaturation in the presence of various concentrations of urea. Circular Dichroism MRE for MGDF (-O-) and DMPG:MGDF (-●-) is depicted as well as MGDF (-□-) and DMPG:MGDF (-■-) fluorescence emission maximum. The MGDF was *E. coli* derived MGDF 1-163. The DMPG:MGDF ratio was 100:1 (mole:mole).

10

FIGURE 27 is a graphical representation of the fluorescence emission maxima for MGDF (\pm DMPG) and PEG-MGDF (\pm DMPG). The MGDF was *E. coli* derived MGDF 1-163, and the PEG-MGDF was mono-pegylated *E. coli* derived MGDF 1-163. The DMPG:MGDF and DMPG:PEG-MGDF ratio was 100:1 (mole:mole).

15

FIGURE 28 shows the extent of PEG-MGDF (\pm DMPG) adsorption to glass vials at various PEG-MGDF concentrations. The MGDF was *E. coli* derived MGDF 1-163, and the PEG-MGDF was mono-pegylated *E. coli* derived MGDF 1-163. The % recovery of PEG-MGDF (-□-) and DMPG:PEG-MGDF (-O-) was assayed by counting the amount of radiolabeled MGDF recoverable from the glass vials after an 18 hour incubation at room temperature.

25

FIGURE 29 shows the DNA and amino acid sequence of human MGDF (SEQ ID NOs:1 and 2) including a signal peptide (amino acids -21 to -1) and the mature amino acid sequence (1-332).

30

FIGURE 30 shows an example of site-specific MGDF reductive alkylation at the α -amino group of the N-terminal residue using mono-methoxy-polyethylene glycol aldehydes to result in a substantially mono-pegylated product.

35

-14-

FIGURE 31 shows *in vivo* activity of DMPG:MGDF and DMPG:PEG-MGDF in normal mice, in terms of platelet counts. The MGDF was *E. coli* derived MGDF 1-163, and the PEG-MGDF was mono-pegylated *E. coli* derived MGDF 1-163. The DMPG:MGDF and DMPG:PEG-MGDF dose was 100 µg/kg and 300 µg/kg and the lipid:protein ratio was 100:1

10

DETAILED DESCRIPTION

The compositions of the present invention are described in more detail in the discussion that follows and are illustrated by the examples provided below. The examples show various aspects of the invention and include results of stability and biological activity testing of various protein:phospholipid compositions. Surprisingly, the interaction of the proteins with the lipid vesicle directly stabilized the protein structure of the protein, thereby exerting a stabilizing effect on the protein even under conditions which lead to denaturation of the protein in the absence of lipid.

The oral administration of a chemically modified G-CSF:phospholipid composition is also described herein, using G-CSF (as described above) to which polyethylene glycol molecules have been attached.

Contemplated for use in the practice of the present invention are a variety of proteins capable of transitioning into the molten globular state. Exemplary proteins contemplated are cytokines, including various hematopoietic factors such as the aforementioned G-CSF, GM-CSF, MGDF, M-CSF, the interferons (alpha, beta, and gamma), the interleukins (1-11), erythropoietin (EPO), fibroblast growth factor, stem cell factor, nerve growth factor, BDNF, NT3, platelet-derived growth factor, and tumor growth factor

-15-

(alpha, beta). Other proteins may be evaluated for the ability to transition into the MGS. If the protein in question is capable of transitioning into the MGS, the protein in question may then be contacted with a
5 negatively charged liposome vesicle and the stabilizing effects evaluated.

In general, G-CSF useful in the practice of this invention may be a native form isolated pure from mammalian organisms or, alternatively, a product of
10 chemical synthetic procedures or of procaryotic or eucaryotic host expression of exogenous DNA sequences obtained by genomic or cDNA cloning or by gene synthesis. Suitable procaryotic hosts include various bacterial (e.g., *E. coli*) cells. Suitable eucaryotic
15 hosts include yeast (e.g., *S. cerevisiae*) and mammalian (e.g., Chinese hamster ovary, monkey) cells. Depending upon the host employed, the G-CSF expression product may be glycosylated with mammalian or other eucaryotic carbohydrates, or it may be non-glycosylated. The
20 present invention contemplates the use of any and all such forms of G-CSF, although recombinant G-CSF, especially *E. coli* derived, is preferred for reasons of greatest commercial practicality.

The G-CSF to be chemically modified for use in
25 the present invention may also be either natural human G-CSF (nhG-CSF) or the product of a recombinant nucleic acid process, such as prokaryotic or eukaryotic host cell expression. In general, chemical modification contemplated is the attachment of a chemical moiety to
30 the G-CSF molecule itself. A review article describing protein modification and fusion proteins is Francis, *Focus on Growth Factors* 3: 4-10 (May 1992) (published by Mediscript, Mountview Court, Friern Barnet Lane, London N20 0LD, UK). For example, see EP 0 401 384, entitled,
35 "Chemically Modified Granulocyte Colony Stimulating Factor," which describes materials and methods for

-16-

preparing G-CSF to which polyethylene glycol molecules are attached. The attachment may be by bonding, directly to the protein or to a moiety which acts as a bridge to the active agent. Covalent bonding is preferred as the most stable for attachment. The chemical modification may contribute to the controlled, sustained or extended effect of the G-CSF. This may have the effect, for example, of controlling the amount of time the chemically modified G-CSF takes to reach the circulation. An example of a chemical modifier is polyethylene glycol compositions, including derivatives thereof.

Contemplated for use in the practice of this invention are any chemically modified G-CSF preparations which permit efficacy upon administration. Efficacy may be determined by known methods, as a practitioner in the art will recognize. Pegylated G-CSF, especially pegylated *E. coli* derived G-CSF, and more particularly, tri-tetra pegylated *E. coli* derived G-CSF is preferred.

G-CSF has been reported to be most stable under acidic conditions, despite the fact that in the pH range of 2.5 - 5.0, a conformational change occurs which involves a loosening of the tertiary structure and an increase in alpha helical content. Narhi et al., *J. Protein Chem.* 10, 359-367, (1991). This conformational change is characteristic of the molten globular state (MGS). Thus, as is the case for a formulator working with other proteins capable of transitioning into the MGS, a formulator working with G-CSF must protect against thermally-induced unfolding of secondary and tertiary structure in order to prevent aggregation and denaturation.

The GM-CSF useful in the present invention may be a native form isolated pure from mammalian organisms or a product of procaryotic or eucaryotic host expression of exogenous DNA sequences obtained by

-17-

genomic or cDNA cloning or by gene synthesis. Suitable procaryotic hosts include various bacterial (e.g., *E. coli*) cells. Suitable eucaryotic hosts include yeast (e.g., *S. cerevisiae*) and mammalian (e.g., Chinese hamster ovary, monkey) cells. Depending upon the host employed, the GM-CSF expression product may be glycosylated with mammalian or other eucaryotic carbohydrates, or it may be non-glycosylated. The present invention contemplates the use of any and all such forms of GM-CSF, although recombinant GM-CSF, especially *E. coli* derived, is preferred for reasons of greatest commercial practicality.

The term "MGDF", as used herein, includes naturally occurring MGDF, truncations of naturally occurring MGDF as well as non-naturally occurring polypeptides having an amino acid sequence and glycosylation sufficiently duplicative of that of naturally occurring MGDF to allow possession of a biological activity of specifically stimulating growth, development and/or production of megakaryocytes and/or platelets.

In a preferred embodiment, MGDF is the product of the expression of an exogenous DNA sequence that has been transfected into a eukaryotic or procaryotic host cell; that is, in a preferred embodiment the MGDF is "recombinant MGDF". The preferred eucaryotic host is mammalian, particularly preferably CHO cells, and the preferred procaryotic host is bacteria, particularly preferably *E. coli*. Recombinant MGDF is advantageously produced according to the procedures described herein and in the publications cited herein regarding cloning and expression of MGDF.

Some additional preferred MGDF molecules have the following amino acid sequences, based on FIGURE 29 herein:

-18-

	MGDF 1-332	amino acids 1-332 of FIG. 29
	MGDF 1-191	amino acids 1-191 of FIG. 29
	MGDF 1-183	amino acids 1-183 of FIG. 29
	MGDF 1-174	amino acids 1-174 of FIG. 29
5	MGDF 1-163	amino acids 1-163 of FIG. 29
	MGDF 1-153	amino acids 1-153 of FIG. 29
	MGDF 1-152	amino acids 1-152 of FIG. 29
	MGDF 1-151	amino acids 1-151 of FIG. 29
	MGDF 7-332	amino acids 7-332 of FIG. 29
10	MGDF 7-191	amino acids 7-191 of FIG. 29
	MGDF 7-183	amino acids 7-183 of FIG. 29
	MGDF 7-174	amino acids 7-174 of FIG. 29
	MGDF 7-163	amino acids 7-163 of FIG. 29
	MGDF 7-153	amino acids 7-153 of FIG. 29
15	MGDF 7-152	amino acids 7-152 of FIG. 29
	MGDF 7-151	amino acids 7-151 of FIG. 29

In each of the above cases, Met-Lys may further be included in the N-terminus thereof.

Also contemplated for use in the present invention are various analogs of MGDF. As used herein the phrase "analog of MGDF" refers to MGDF with one or more changes in the amino acid sequence of MGDF which result in a change in the type (N- or O-linked), number, or location of sites for carbohydrate attachment. The MGDF analog(s) retain(s) at least equivalent biological activity as compared to natural sequence MGDF (e.g., human MGDF) and may possess substantially higher activity, as measured in assays for biological activity. The resulting analogs may have fewer or more (preferably more) carbohydrate chains than natural human/recombinant MGDF.

Also included within the analogs of this invention are analogs which have one or more amino acids extending from the carboxy terminal end of MGDF wherein the carboxy terminal extension provides at least one

-19-

additional carbohydrate site. The carboxy terminus of MGDF will vary depending upon the particular form of MGDF used (e.g., MGDF 1-332 amino acids, or MGDF 1-163 amino acids). An additional carbohydrate site may be added to the carboxy terminus of an MGDF species by adding amino acids to the carboxy terminus, such amino acids containing one or more N- or O-linked glycosylation sites.

The present invention also broadly includes chemically modified MGDF compositions. In general, the chemical modification contemplated is an MGDF product wherein said MGDF protein is linked to at least one polyethylene glycol molecule (i.e., pegylated MGDF). Pegylation of MGDF may be carried out by any of the pegylation reactions known in the art. See, for example: *Focus on Growth Factors* 3(2): 4-10 (1992); EP 0 154 316; EP 0 401 384; and the other publications cited herein that relate to pegylation. Preferably, the pegylation is carried out via an acylation reaction or an alkylation reaction with a reactive polyethylene glycol molecule (or an analogous reactive water-soluble polymer).

Pegylation by acylation generally involves reacting an active ester derivative of polyethylene glycol (PEG) with an MGDF protein. Any known or subsequently discovered reactive PEG molecule may be used to carry out the pegylation of MGDF. A preferred activated PEG ester is PEG esterified to N-hydroxysuccinimide ("NHS"). As used herein, "acylation" is contemplated to include without limitation the following types of linkages between MGDF and a water soluble polymer such as PEG: amide, carbamate, urethane, and the like. See *Bioconjugate Chem.* 5:133-140 (1994). Reaction conditions may be selected from any of those known in the pegylation art or those subsequently developed, but should avoid

-20-

conditions such as temperature, solvent, and pH that would inactivate the MGDF species to be modified.

Pegylation by acylation will generally result in a poly-pegylated MGDF product, wherein the lysine ϵ -amino groups are pegylated via an acyl linking group. Preferably, the connecting linkage will be an amide. Also preferably, the resulting product will be substantially only (e.g., $\geq 95\%$) mono, di- or tri-pegylated. However, some species with higher degrees of pegylation (up to the maximum number of lysine ϵ -amino acid groups of MGDF plus one α -amino group at the amino terminus of MGDF) will normally be formed in amounts depending on the specific reaction conditions used. If desired, more purified pegylated species may be separated from the mixture, particularly unreacted species, by standard purification techniques, including, among others, dialysis, salting-out, ultrafiltration, ion-exchange chromatography, gel filtration chromatography and electrophoresis.

Pegylation by alkylation generally involves reacting a terminal aldehyde derivative of PEG with a protein such as MGDF in the presence of a reducing agent. Pegylation by alkylation can also result in poly-pegylated MGDF. In addition, one can manipulate the reaction conditions as described herein to favor pegylation substantially only at the α -amino group of the N-terminus of the MGDF species (i.e., a mono-pegylated species). An exemplary reductive alkylation reaction with MGDF to yield a monopegylated product is shown in FIGURE 30. In either case of monopegylation or polypegylation, the PEG groups are preferably attached to the protein via a $-\text{CH}_2\text{-NH}-$ group. With particular reference to the $-\text{CH}_2-$ group, this type of linkage is referred to herein as an "alkyl" linkage.

Derivatization via reductive alkylation to produce a monopegylated product exploits differential

-21-

reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in MGDF. The reaction is performed at a pH (see below) which allows one to take advantage of the pK_a differences between the ϵ -amino groups of the lysine residues and that of the α -amino group of the N-terminal residue of the protein. By such selective derivatization, attachment of a water soluble polymer that contains a reactive group such as an aldehyde, to a protein is controlled: the conjugation with the polymer takes place predominantly at the N-terminus of the protein and no significant modification of other reactive groups, such as the lysine side chain amino groups, occurs.

Thus, in a preferred aspect, the present invention relates to pegylated MGDF, wherein the PEG group(s) is (are) attached via acyl or alkyl groups. As discussed above, such products may be mono-pegylated or poly-pegylated (e.g., containing 2-6, preferably 2-5, PEG groups). The PEG groups are generally attached to the protein at the α or ϵ amino groups of amino acids, but it is also contemplated that the PEG groups could be attached to any amino group attached to the protein, which is sufficiently reactive to become attached to a PEG group under suitable reaction conditions.

The polymer molecules used in both the acylation and alkylation approaches may be selected from among water soluble polymers or a mixture thereof. The polymer selected should be water soluble so that the protein to which it is attached does not precipitate in an aqueous environment, such as a physiological environment. The polymer selected should be modified to have a single reactive group, such as an active ester for acylation or an aldehyde for alkylation, preferably, so that the degree of polymerization may be controlled as provided for in the present methods. A preferred

-22-

reactive PEG aldehyde is polyethylene glycol propionaldehyde, which is water stable, or mono C1-C10 alkoxy or aryloxy derivatives thereof (see, U.S. Patent 5,252,714). The polymer may be branched or unbranched.

5 Preferably, for therapeutic use of the end-product preparation, the polymer will be pharmaceutically acceptable. The water soluble polymer may be selected from the group consisting of, for example, polyethylene glycol, monomethoxy-polyethylene glycol, dextran, poly-
10 (N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol) and polyvinyl alcohol. For the acylation reactions, the polymer(s) selected should have a single
15 reactive ester group. For the present reductive alkylation, the polymer(s) selected should have a single reactive aldehyde group. Generally, the water soluble polymer will not be selected from naturally-occurring glycosyl residues since these are usually made more
20 conveniently by mammalian recombinant expression systems. The polymer may be of any molecular weight, and may be branched or unbranched.

A particularly preferred water-soluble polymer for use herein is polyethylene glycol, abbreviated PEG.

25 As used herein, polyethylene glycol is meant to encompass any of the forms of PEG that have been used to derivatize other proteins, such as mono-(C1-C10) alkoxy- or aryloxy-polyethylene glycol. Methods for preparing pegylated MGDF will generally comprise the steps of (a)
30 reacting an MGDF polypeptide with polyethylene glycol (such as a reactive ester or aldehyde derivative of PEG) under conditions whereby MGDF becomes attached to one or more PEG groups, and (b) obtaining the reaction product(s). In general, the optimal reaction conditions
35 for the acylation reactions will be determined case-by-case based on known parameters and the desired

-23-

result. For example, the larger the ratio of PEG: protein, the greater the percentage of poly-pegylated product.

Another important consideration is the molecular weight of the polymer. In general, the higher the molecular weight of the polymer, the fewer number of polymer molecules which may be attached to the protein. Similarly, branching of the polymer should be taken into account when optimizing these parameters. Generally, the higher the molecular weight (or the more branches) the higher the polymer:protein ratio. In general, for the pegylation reactions contemplated herein, the preferred average molecular weight is about 2kDa to about 100kDa (the term "about" indicating ± 1 kDa). The preferred average molecular weight is about 5kDa to about 50kDa, particularly preferably about 12kDa to about 25kDa, and most preferably 20kDa. The ratio of water-soluble polymer to MGDF protein will generally range from 1:1 to 100:1, preferably (for polypegylation) 1:1 to 20:1 and (for monopegylation) 1:1 to 5:1.

Using the conditions indicated above, reductive alkylation will provide for selective attachment of the polymer to any MGDF protein having an α -amino group at the amino terminus, and provide for a substantially homogenous preparation of monopolymer/MGDF protein conjugate. The term "monopolymer/MGDF protein conjugate" is used here to mean a composition comprised of a single polymer molecule attached to an MGDF protein molecule. The monopolymer/MGDF protein conjugate preferably will have a polymer molecule located at the N-terminus, but not on lysine amino side groups. The preparation will preferably be greater than 90% monopolymer/MGDF protein conjugate, and more preferably greater than 95% monopolymer MGDF protein conjugate, with the remainder of observable molecules being unreacted (i.e., protein lacking the polymer moiety).

-24-

The examples below provide for a preparation which is at least about 90% monopolymer/ protein conjugate, and about 10% unreacted protein. The monopolymer/protein conjugate has biological activity.

5 The lipid vesicles useful in the compositions of the present invention are those negatively charged liposomes capable of interacting with the protein in question. Particular liposomes contemplated for use include dioleoylphosphatidylglycerol (DOPG),
10 dimyristoylphosphatidylglycerol (DMPG),
dipalmitoylphosphatidylglycerol (DPPG),
eggphosphatidylglycerol,
dioleoylphosphatidylethanolamine (DOPE),
eggphosphatidylethanolamine, dioleoylphosphatidic acid
15 (DOPA), dimyristoylphosphatidic acid (DMPA),
dipalmitoylphosphatidic acid (DPPA),
dioleoylphosphatidylserine (DOPS),
dimyristoylphosphatidylserine (DMPS),
dipalmitoylphosphatidylserine (DPPS),
20 eggphosphatidylserine, lysophosphatidylglycerol,
lysophosphatidylethanolamine, lysophosphatidylserine.
Depending on the particular liposome utilized, the amount of liposome could vary.

 The protein:phospholipid compositions
25 preferably include a buffering agent to maintain the pH of the solution within a desired range. Preferred agents include sodium acetate, sodium phosphate, and sodium citrate. Mixtures of these buffering agents may also be used. The amount of buffering agent useful in
30 the composition depends largely on the particular buffer used and the pH of the solution. For example, acetate is a more efficient buffer at pH 5 than pH 6 so less acetate may be used in a solution at pH 5 than at pH 6. The preferred pH range for the compositions of the
35 present invention is pH 3.0 - 7.5.

-25-

The compositions of the present invention may further include an isotonicity adjusting agent to render the solution isotonic and more compatible for injection. The most preferred agent is sodium chloride within a concentration range of 0 - 150 mM.

Also comprehended by the invention are pharmaceutical compositions comprising effective amounts of polypeptide products of the invention together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. Such compositions will influence the physical state, stability, and bioavailability of the protein. See, e.g., *Remingtons Pharmaceutical Sciences*, 18th Edition, 1435-1712 (Mack Publishing Co., Easton, PA., 1990) which is herein incorporated by reference. What constitutes an effective amount of the protein in a particular case will depend on a variety of factors which the knowledgeable practitioner will take into account, including the desired therapeutic result, the severity of the condition or illness being treated, the physical condition of the subject, and so forth.

In a preferred embodiment involving *E. coli* derived rhG-CSF, the liposome vesicle used is DOPG with a 50:1 ratio of DOPG:G-CSF, at pH 4.5, containing 10 mM sodium acetate.

In a preferred embodiment involving *E. coli* derived rhGM-CSF, the liposome vesicle used is DMPG with a 17:1 ratio of DMPG:GM-CSF, at pH 7.0, in phosphate buffered saline (PBS).

In a preferred embodiment involving *E. coli* derived rhG-CSF which has been chemically modified (pegylated), the rhG-CSF is tri-tetra pegylated, the liposome vesicle used is DMPG with a 17:1 ratio of DMPG:PEG-G-CSF, at pH 4.5.

In a preferred embodiment involving *E. coli* derived MGDF 1-163, the liposome vesicle used is DMPG

-26-

with a 100:1 ratio of DMPG:MGDF, at pH 5.0, in 10mM sodium acetate 5% sorbitol.

5 In a preferred embodiment involving *E. coli* derived MGDF 1-163 which has been chemically modified (pegylated), the MGDF is mono-pegylated (20kDa) via reductive alkylation, the liposome vesicle used is DMPG with a 100:1 ratio of DMPG:MGDF, at pH 5.0, in 10mM sodium acetate 5% sorbitol.

10 In a preferred embodiment involving CHO derived MGDF 1-332, the liposome vesicle used is DMPG with a 100:1 ratio of DMPG:MGDF, at pH 5.0, in 10mM sodium acetate 5% sorbitol.

15 Although the invention has been described and illustrated with respect to specific protein:lipid compositions and treatment methods, it will be apparent to one of ordinary skill that a variety of related compositions, and treatment methods may exist without departing from the scope of the invention.

20 The following examples will illustrate in more detail the various aspects of the present invention.

EXAMPLE 1

25 Initial experiments were performed to examine the possibility of incorporating recombinant human G-CSF (rhG-CSF) into a lipid vesicle. The rhG-CSF was produced using recombinant DNA technology in which *E. coli* cells were transfected with a DNA sequence encoding human G-CSF as described in U.S. Patent No. 4,810,643 to Souza. The rhG-CSF was prepared as a 4 mg/ml solution in dilute HCl, pH 4.0. All lipids were obtained from Avanti Polar Lipids (Alabaster, Ala) and were stored at -20°C under nitrogen at a final concentration of 100
35 mg/ml in chloroform.

-27-

Preparation of G-CSF:Phospholipid Complexes

To prepare lipid vesicles for combination with G-CSF, 30 μ mole of the appropriate lipid was dispensed into a glass tube and dried to a thin film using a stream of nitrogen gas. The lipid films were desiccated for at least two hours under vacuum to remove any traces of chloroform. The lipid films were hydrated in 1 ml of either distilled de-ionized water (ddH₂O), phosphate buffered saline, pH 7.2 (Gibco/BRL "D-PBS") or 150mM NaCl. The samples were then sonicated in a bath-type sonicator (Laboratory Supplies, Hicksville, N.Y.). Sonication was continued until the samples were optically clear (usually between 10-15 minutes). The samples were stored at 4°C under nitrogen until use. The final lipid concentration was 30 mM. Alternatively, the lipid vesicles could be prepared by taking 300 μ mole of lipid and drying under nitrogen and dessicating as described above. The dry lipid films were hydrated in 10 ml of appropriate aqueous solution as described above. The samples were then microfluidized in a bench scale emulsifier (Microfluidics Model 110S, Microfluidics, Inc. Cambridge, MA) operating at 10,000 psi. The samples were recycled through the instrument for 10 cycles. The microfluidized samples were then stored at 4°C as described above.

The G-CSF:phospholipid complexes were prepared by mixing G-CSF (as described above) with a particular lipid (as described above). Mixing was accomplished by vortexing, stirring, or gentle shaking. Various mole ratios of lipid:G-CSF were prepared to evaluate membrane insertion and stabilization of protein. For example, to prepare a 3 ml sample (in water) which is 0.2 mg/ml G-CSF at a 40:1 mole ratio of lipid:G-CSF, 150 μ l of G-CSF stock is combined with 44 μ l of lipid (30 mM stock, prepared in water by sonication) and water is

-28-

added to achieve a final sample volume of 3 ml. A five minute incubation is recommended (but not necessary), and was used here before using or assaying the sample.

5 G-CSF can also be combined with the hydrated lipid prior to microfluidization. Subsequent microfluidization of the mixtures as described above leads to incorporation of G-CSF into the lipid membrane.

Analysis of the G-CSF: Phospholipid Complexes

10

1. Tryptophan emission spectra.

There are two tryptophan residues in rhG-CSF that are quite sensitive to local environmental conditions. Therefore, analysis was performed to determine the rhG-CSF tryptophan fluorescence when the rhG-CSF is contacted with a liposome. A blue shift in fluorescence emission maximum would suggest that the tryptophans are in a more hydrophobic environment and therefore the rhG-CSF was embedded in the lipid membranes. An excellent review of tryptophan fluorescence analysis is *Principles of Fluorescence Microscopy*, by J. Lakowicz, Chap 11 (Plenum Press, New York, 1983).

25 Tryptophan fluorescence of the G-CSF:lipid complexes (as described above) was assayed by exciting the samples at 280 nm and while scanning the emission from 285 nm to 420 nm in 1nm increments at a rate of 1 nm/sec. The sample volume was 3 ml and the final concentration of G-CSF was 0.2 mg/ml for all samples. The lipid:G-CSF ratios varied. All fluorescence measurements were carried out using a PTI Alphascan fluorometer (South Brunswick, NJ). All measurements were performed at 25°C and this temperature was maintained through the use of a water-jacketed cuvette holder connected to a circulating water bath. Emission

-29-

spectra were collected and analyzed using the data software provided by PTI.

The fluorescence spectra of rhG-CSF in the presence and absence of small unilamellar vesicles composed of DOPG is shown in FIGURE 1. rhG-CSF has an emission maximum at 334 nm in the absence of DOPG vesicles. In the presence of DOPG at a 100:1 lipid:protein ratio, rhG-CSF tryptophan fluorescence exhibits a blue shift in fluorescence emission maximum to 327 nm and a dramatic increase in fluorescence intensity. The low wavelength of the fluorescence emission in the presence of DOPG suggests that the tryptophans are in an environment more hydrophobic than the native protein. As demonstrated in FIGURE 2, the fluorescence shifts depend on the mole ratio of DOPG:G-CSF and membrane insertion is detectable once a 10:1 ratio of DOPG:G-CSF is reached.

2. Iodide quenching experiments.

Iodide is an efficient collisional quencher of tryptophan fluorescence, but cannot penetrate lipid membranes. Therefore, efficient quenching of tryptophan fluorescence by iodide indicates exposure of the residues to the bulk aqueous solvent while protection from iodide quenching occurs when protein tryptophans are sequestered away from the aqueous solvent. In these experiments, G-CSF and a DOPG:G-CSF composition (100:1 lipid:protein ratio) was used. After initial readings (F_0) on the samples were taken and recorded, fluorescence intensity was measured after addition of increasing amounts of potassium iodide (KI) (5M stock). Both the sample and KI solutions were prepared to contain 1 mM Na_2SO_3 (final concentration) as described by Lee et al, *Biochem. Biophys. Acta*, 984: 174-182 (1989) and Le Doan et al., *Biochem. Biophys. Acta*, 858:

-30-

1-5 (1986). The addition of Na_2SO_3 prevents the formation of I_2 which can partition into nonpolar regions of proteins and membranes. The data were analyzed by the Stern-Volmer equation ($F_0/F = 1 + K_{\text{KI}}[\text{KI}]$), where F_0 and F are the fluorescence intensities of samples in the absence and presence, respectively, of KI at concentration $[\text{KI}]$. K_{KI} is the Stern-Volmer quenching constant for KI quenching of G-CSF tryptophan residues; Lehrer, S., *Biochemistry* 10: 3254-3263 (1979).

The Stern-Volmer plots of the data are shown in FIGURE 3. In the absence of DOPG vesicles, rhG-CSF fluorescence is efficiently quenched by KI. In the presence of DOPG, the Stern-Volmer plot of the data is linear, indicating that iodide has poor access to both tryptophans. The data shows that the tryptophan residue which is iodide-accessible in the absence of DOPG becomes iodide-inaccessible in the presence of DOPG. Therefore, the portion of rhG-CSF containing this tryptophan must be embedded in the DOPG bilayer.

3. Energy transfer measurements.

As previously shown, energy transfer can occur between tryptophan donors and lipid soluble fluorescent acceptors such as pyrene decanoic acid, since the excitation spectrum of this probe significantly overlaps the emission spectra of tryptophan. Friere et al., *Biochemistry* 22: 1675-1680 (1983). If the protein inserts into lipid membranes, energy transfer from tryptophan to pyrene will lead to quenching of the tryptophan fluorescence. In this experiment, the tryptophan emission intensity of various lipid:G-CSF complexes was recorded before (F_0) and after (F) addition of various amounts of pyrene decanoic acid (30 $\mu\text{g/ml}$ stock in tetrahydrofuran). The samples were

-31-

stirred continuously during pyrene decanoic acid addition to promote mixing between pyrene decanoic acid and the sample. The ratio of F/F_0 is proportional to the amount of energy transfer occurring between G-CSF tryptophans and the hydrophobic energy acceptor pyrene decanoic acid.

FIGURE 4 shows the quenching profile for rhG-CSF in the presence of DOPG (100:1 lipid:protein ratio) as a function of added pyrene decanoic acid. The quenching occurs at very low pyrene decanoic acid concentrations (<1 mole %), so the effect of the fluorescent probe on the membrane structure and behavior is minimal. Since pyrene decanoic acid can be expected to rapidly partition into lipid bilayers, the present data indicate that rhG-CSF is embedded in DOPG membranes deep enough to allow efficient energy transfer from tryptophan to the pyrene acceptor. Energy transfer was confirmed by examining the excitation spectra of pyrene decanoic acid-labeled DOPG vesicles in the presence and absence of rhG-CSF.

The analysis above shows that rhG-CSF can closely interact with an unsaturated phospholipid like DOPG. In the presence of DOPG vesicles, a rhG-CSF tryptophan is protected from a water soluble fluorescence quencher but is susceptible to quenching via energy transfer to a hydrophobic fluorescent probe. Taken together, the data show that rhG-CSF can insert into membranes composed of DOPG. Membrane insertion is detectable once a 10:1 ratio (lipid:G-CSF) is reached, and this number may represent the number of lipids which surround the inserted portion of the protein.

35

-32-

EXAMPLE 2

In this example, the ability of rhG-CSF to interact with other phospholipids was determined using comparisons of F/F_0 intensity and emission maximums as described above. In each instance, the mole ratio of lipid:rhG-CSF was 100:1.

FIGURE 5 shows the F/F_0 data for rhG-CSF in the absence and presence of various lipids. FIGURE 6 shows the emission maximum data for the same compositions. The data in FIGURE 5 and FIGURE 6 demonstrates that, in addition to DOPG, rhG-CSF can insert into DMPG, DPPG, and less efficiently, into the phosphatidylethanolamines (PE's) and the phosphatidylserines (PS's). In addition, NG-DOPE (DOPE sample where the PE headgroup was made more negative) was found to provide for improved insertion of the rhG-CSF than DOPE.

DOPC, DMPC and DPPC are neutral lipids and these vesicles had little if no effect on either the emission maximum or the fluorescence intensity of rhG-CSF, indicating that no interaction took place with these phospholipids (see FIGURES 5 and 6, and FIGURE 7, curve 2).

The data above demonstrate that a protein capable of transitioning into the molten globular state can insert in various lipid vesicles. However, this rhG-CSF:lipid interaction only occurs when a negatively charged lipid vesicle is used. Among the negatively charged lipid vesicles, those vesicles with the greater negative charge seem to provide for a stronger rhG-CSF:lipid interactions.

-33-

EXAMPLE 3

In this example, the effect of the DOPG:rhG-CSF interaction as it relates to protein stability was determined. Circular dichroism measurements were made on a Jasco J-720 instrument equipped with a Peltier-type thermostatted cell holder and a magnetic stirrer. Circular dichroism at 222 nm was measured using a final rhG-CSF concentration of 80 μ g/ml, pH 6.0. Differential scanning calorimetry measurements were made using a Microcal MC-2 calorimeter. Samples of rhG-CSF (1 mg/ml, in water) or DOPG:rhG-CSF (45:1 mole/mole, in water) were scanned at a rate of 90°C/hour. Data were stored and analyzed using the Microcal software.

Temperature-induced changes in the alpha helicity of G-CSF can be followed by measuring circular dichroism (222 nm) as a function of increasing temperatures. The thermally-induced unfolding of rhG-CSF at pH 6.0 is shown in FIGURE 8. The curve indicates that a fairly sharp transition occurs at ~60-70°C which leads to loss of alpha helicity. After this transition the rhG-CSF irreversibly precipitates from solution. The temperature range of the unfolding is similar to the melting temperature of rhG-CSF at pH 7.0 as determined by differential scanning calorimetry as shown in FIGURE 9.

By contrast, DOPG:rhG-CSF samples show a gradual loss of alpha helicity with increasing temperature and, unlike rhG-CSF alone, the temperature-induced unfolding of DOPG:rhG-CSF does not appear to be cooperative (see FIGURE 8). This conclusion is also demonstrated by the lack of a melting transition as shown by differential scanning calorimetry (FIGURE 9). Remarkably, DOPG:rhG-CSF samples can recover alpha helicity after heating to 95°C and can be

-34-

repeatedly cycled between 95°C and 10°C with full recovery of helicity upon cooling (see FIGURE 10). rhG-CSF alone under these conditions is irreversibly unfolded and precipitates from solution.

5 The effects of DMPG and DPPG on G-CSF circular dichroism was also examined. A 150:1 lipid:rhG-CSF ratio was used and, as was the case with DOPG, DMPG and DPPG also stabilize the secondary structure of rhG-CSF (FIGURES 11-13).

10

 These data demonstrate that the interaction of rhG-CSF with DOPG, DMPG and DPPG enhances the stability of the protein under conditions where rhG-CSF alone is unstable. The interaction directly stabilizes the
15 secondary and tertiary structure of rhG-CSF.

EXAMPLE 4

 In this example, the effect of the
20 rhG-CSF:DOPG interaction as it relates to the biological activity of rhG-CSF was determined. The *in vitro* activity of rhG-CSF was assayed utilizing the G-CSF dependent uptake of [³H]-thymidine by murine bone marrow cells as described in Zsebo et al., *Immunobiology* 172:
25 175-184 (1986). All activity assays were performed in triplicate. *In vivo* activity was determined by subcutaneous injection of hamsters (rhG-CSF dose of 100 µg/kg) and measurements of white blood cell (WBC) count.

30 1. *In vitro* activity

 A. The specific activity of rhG-CSF in the absence and presence of DOPG was determined. Heat treated rhG-CSF and DOPG:rhG-CSF samples were also
35 tested. The results are summarized in TABLE 1.

-35-

TABLE 1

	<u>Sample</u>	<u>Specific activity (U/mg/protein)</u>
5	rhG-CSF	0.66 \pm 0.09
	rhG-CSF (heated) ^a	Not Detectable
10	DOPG:rhG-CSF ^b	0.61 \pm 0.11
	DOPG:rhG-CSF ^b (heated) ^a	0.52 \pm 0.08

15 ^aSample was incubated for 10 minutes at 85°C in a water bath prior to performing the assay.

^bDOPG:rhG-CSF ratio of 50:1 (mole/mole).

 As shown in TABLE 1, insertion into DOPG
 20 bilayers does not adversely affect the biological activity of rhG-CSF. After heating to 85°C for 10 minutes, rhG-CSF has undetectable activity and the protein precipitates. After similar treatment, DOPG:rhG-CSF retains ~85% of the activity of unheated
 25 rhG-CSF and fully recovers secondary structure upon cooling.

 B. The ability of various lipids to stabilize rhG-CSF during freeze drying was also studied. Samples of rhG-CSF in combination with various lipids were
 30 freeze dried and assayed (as described above) for activity. DOPG, DMPG, and DPPG when mixed with rhG-CSF allow ~100% retention of rhG-CSF bioactivity after freeze drying (FIGURE 14). rhG-CSF alone did not survive the freeze-drying process.

35 2. *In vivo* activity

 The activity (WBC count) of rhG-CSF in the absence and presence of lipid was determined. Activity
 40 was measured after subcutaneous injection (rhG-CSF dose

-36-

of 100 µg/kg) on day 0. Five different lipid:rhG-CSF complexes were assayed and in each instance the lipid:rhG-CSF complex retained *in vivo* activity (FIGURES 15 and 16).

5

The studies above demonstrate that insertion into negatively charged lipid bilayers does not adversely affect the biological activity of rhG-CSF. Additionally, it appears that the protective effect of the lipid protects rhG-CSF during the freeze-drying process.

EXAMPLE 5

15 In this example, chemically modified G-CSF (pegylated G-CSF (PEG-G-CSF)) and G-CSF obtained as a product of eucaryotic host cell expression (CHO-G-CSF) were tested for their ability to interact with negatively charged lipid vesicles. For the CHO-G-CSF, 20 the determinations were made using comparisons of F/F_0 intensity and emission maximums (as described in Example 1 above). In each instance, the mole ratio of lipid:protein was 100:1. For the PEG-G-CSF, the determination was based upon circular dichroism 25 analysis.

The CHO-G-CSF used was produced using recombinant DNA technology in which Chinese Hamster Ovary (CHO) cells were transfected with a DNA sequence encoding human G-CSF as described in U.S. Patent No. 30 4,810,643 to Souza. The CHO-G-CSF was prepared as a .6 mg/ml solution in PBS, pH 7.0. CHO-G-CSF was shown to interact with DOPG in a manner similar to rhG-CSF, with each sample showing increased fluorescence intensity in the presence of DOPG, as well as a blue 35 shift in emission maximum in the presence of DOPG (FIGURES 17 and 18). Therefore, the DOPG interaction is

-37-

not due to some peculiarity of the recombinant form of G-CSF.

PEG-G-CSF used in these experiments was tri-tetra pegylated *E. coli* derived G-CSF (using PEG 6000).
5 DMPG:PEG-G-CSF (17:1 mole/mole) samples were prepared using procedures described above. The DMPG:PEG-G-CSF samples were found to fully recover secondary structure after heating (FIGURE 19). Despite the presence of the PEG molecules, the derivatized protein was able interact
10 with the lipid in the same way as the native protein.

The data above show that the stabilizing effects associated with G-CSF interaction with a negatively charged lipid vesicle is not unique only to
15 rhG-CSF obtained as a product of procaryotic host cell expression. A chemically modified protein capable of transitioning to a MGS and contacted with a liposome vesicle, here PEG-G-CSF:DMPG, also exhibited stabilizing effects.

20

EXAMPLE 6

In this example, the effects of DMPG and DPPG on GM-CSF was studied. The GM-CSF was recombinant human
25 GM-CSF as described in U.S. Patent No. 5,047,504 to Boone, and prepared as a 1 mg/ml solution in phosphate buffered saline (PBS), pH 7.0. A lipid:GM-CSF ratio of 17:1 was used and thermal stability was measured using circular dichroism analysis as described above. DMPG
30 and DPPG can lead to better thermal stability of GM-CSF, i.e., recovery of secondary structure after heating (FIGURES 20a & 20b).

These data provide another example of a
35 protein, capable of transitioning into the molten globular state, interacting with a negatively charged

-38-

lipid vesicle to provide better thermal stability to the protein.

EXAMPLE 7

5

In this example, a DOPG:PEG-G-CSF complex was used to evaluate the possibility of increasing the therapeutic response to G-CSF after enteral administration. For this experiment, the DOPG was prepared as described in EXAMPLE 1 and the PEG-G-CSF was prepared as described in EXAMPLE 5. 100 μ mole of lipid (797 μ l) were dried under vacuum and then 1 ml of milli Q water was added to make a 100mM solution of the lipid. This solution was sonicated for 5 minutes in a sonicating water bath (Model G 112SP1T from Lab. Supply Inc., Hicksville, NY) or until the lipid solution was clear. 9 μ mole of the DOPG solution (90 μ l) was added to 90 nmol of native rhG-CSF or PEG-G-CSF in 1 mM HCl. The solution was vortexed and brought to a final volume of 2 ml with 1 mM HCl. For intraduodenal administration into rats, the material was placed in an osmotic pump which was implanted into the animal. The release of the material occurs over 24 hours.

The results of the total WBC analysis for the animals receiving both rhG-CSF and PEG-G-CSF with and without lipid are shown in FIGURE 21. FIGURE 21a shows that infusion of native G-CSF fails to stimulate a WBC response as compared to vehicle control. The addition has little impact on the therapeutic response of the animals to rhG-CSF.

The response of the rats to the pegylated G-CSF is shown in FIGURE 21b. One can see that the PEG-G-CSF alone has stimulated a WBC response. The elevation of WBC is sustained out to 48 hours before returning to baseline. The PEG-G-CSF formulated with DOPG also stimulates a WBC response, and this response

-39-

is nearly 2-fold greater than for PEG-G-CSF alone. These results are confirmed by the measured serum levels of PEG-G-CSF after the infusion (FIGURE 22).

These data demonstrate that including an anionic lipid such as DOPG in an oral formulation of PEG-G-CSF appears to increase the therapeutic response elicited by the derivatized protein. The mechanism involved is not currently understood.

EXAMPLE 8

In this example, the effects of DMPG on MGDF was studied. The MGDF was recombinant human *E. coli* derived MGDF 1-163 prepared as a 1.0 mg/ml solution in 10mM sodium acetate, 5% sorbitol, at pH 5.0. The DMPG:MGDF complexes were prepared as described in EXAMPLE 1.

Analysis of the DMPG:MGDF Complexes

1. Tryptophan emission spectra.

There is one tryptophan residue in MGDF (position 51) that was used to monitor the interaction of MGDF with DMPG vesicles. Tryptophan fluorescence of the DMPG:MGDF complexes was assayed as described in EXAMPLE 1, using an MGDF concentration of 0.1 mg/ml. The fluorescence spectra of MGDF in the presence and absence of small unilamellar vesicles composed of DMPG is shown in FIGURE 22. MGDF has an emission maximum at 336 nm in the absence of DMPG vesicles. In the presence of DMPG at a 100:1 lipid:protein ratio, MGDF tryptophan fluorescence exhibits a blue shift in fluorescence emission maximum to 328 nm. The low wavelength of the fluorescence emission in the presence of DMPG suggests

-40-

that the tryptophans are in an environment more hydrophobic than the native protein. And, as demonstrated in FIGURE 23, the fluorescence shifts depend on the mole ratio of DMPG:MGDF, with membrane insertion detectable once a 8-30:1 ratio of DMPG:MGDF is reached. The fluorescent change is maximal at $\geq 100:1$ mole ratios and the MGDF exhibits an apparently higher affinity for DMPG vesicles as the pH is lowered from pH 7.0 to pH 5.0. This suggests that titration of certain amino acids (e.g., histidine) may be used to enhance or attenuate the interaction.

2. Iodide quenching experiments.

In these experiments, MGDF and a DMPG:MGDF composition (100:1 DMPG:MGDF) was used for iodide quenching experiments as described in EXAMPLE 1. The Stern-Volmer plots of the data are shown in FIGURE 24. In the absence of DMPG vesicles, MGDF fluorescence is efficiently quenched by KI. By contrast, in the presence of DMPG the tryptophan is inaccessible to iodide, indicating that the portion of MGDF containing this tryptophan must be embedded in the DMPG bilayer.

The analysis above shows that as was the case with G-CSF and GM-CSF, MGDF can closely interact with an unsaturated phospholipid like DMPG. In the presence of DMPG vesicles, a MGDF tryptophan is protected from a water soluble fluorescence quencher. Taken together, the data show that MGDF can insert into membranes composed of DMPG. Membrane insertion is detectable once a 8:1 ratio (DMPG:MGDF) is reached, and this number may represent the number of lipids which surround the inserted portion of the protein.

-41-

EXAMPLE 9

In this example, the effect of the DMPG:MGDF interaction as it relates to protein stability was determined. Thermal stability, stability in the presence of urea, and shelf-life stability of MGDF (\pm DMPG) were evaluated. In each of the studies, a 100:1 mole ratio of DMPG:MGDF was used.

1. Thermal Stability.

The circular dichroism (CD at 222 nm) of MGDF alone or inserted into DMPG vesicles was monitored as a function of thermal cycling between 95°C and 10°C as described in EXAMPLE 3, FIGURE 10. The % remaining CD refers to the amount of CD detected (at 10°C) after each cycle (one cycle is 10°C→95°C→10°C) as compared to the CD of an unheated sample of the indicated composition. While MGDF loses more than 70% of its helicity after 3 cycles of heating, DMPG:MGDF fully retains its original alpha helicity under the same conditions (see FIGURE 25).

2. Stability in Presence of Urea

Urea is a chaotropic reagent which can unfold and denature proteins. The equilibrium denaturation of MGDF (\pm DMPG) was monitored by fluorescence, i.e., measure of tertiary structure, and by circular dichroism, i.e., a measure of secondary structure. As depicted in FIGURE 26, as the protein tertiary structure is lost, the tryptophan residues are more exposed to the water phase and the emission wavelength of MGDF is shifted to longer wavelengths; and, as secondary structure is lost, the mean residue elipicity (MRE) becomes less negative as alpha helicity is lost. In the

-42-

absence of DMPG, 50% loss of tertiary structure occurs at around 3M urea, whereas 8M urea is required to achieve 50% loss of structure in the presence of DMPG. Similarly, a 50% loss of MGDF MRE requires 7M urea in the absence of DMPG, compared to 9M urea in the presence of DMPG.

3. Shelf-life Stability

E. coli MGDF 1-163 (\pm DMPG) was stored under the conditions indicated in TABLE 2 below and then examined by size exclusion chromatography (SEC) using a Toso-Haas G3000SWXL column with a mobile phase of 100mM phosphate buffer, 10% ethanol, 0.2% Tween-20, pH 6.9. Samples were diluted with ethanol and Tween-20 to the same concentration as used in the mobile phase and 10-20 μ g sample were injected per run. The column temperature was maintained at 40°C. Any aggregated MGDF which forms elutes earlier than the non-aggregated protein and is quantitated by measuring the area under the curve of the aggregate peak and the monomer peak. Data refer to the % of total MGDF in the aggregate peak.

TABLE 2

25

% aggregation as measured by SEC

<u>Sample</u>	<u>Temperature</u>	<u>5 weeks</u>	<u>11 weeks</u>
MGDF	-80°C	0	0.2
	4°C	0.4	0.6
	37°C	18	39.2
DMPG:MGDF	-80°C	0	0.14
	4°C	0	0
	37°C	1.9	2.5

35

-43-

As shown in TABLE 2, DMPG dramatically reduces the formation of aggregates upon storage. DMPG can thus be used to enhance the shelf-life of MGDF.

5 These data demonstrate that the interaction of MGDF with DMPG vesicles enhances the stability of the protein under conditions where MGDF alone is unstable. The interaction directly stabilizes the secondary and tertiary structure of MGDF in the presence of
10 denaturants like urea, and significantly improves the shelf-life of MGDF at various temperatures.

EXAMPLE 10

15 In this example, chemically modified MGDF 1-163 (mono-pegylated (20kDa) MGDF 1-163 (PEG-MGDF)) was tested for its ability to interact with negatively charged lipid vesicles. For the PEG-MGDF, the determinations were made using comparisons of F/F₀
20 intensity and emission maximums (as described in EXAMPLES 1 and 8 above). In each instance, the mole ratio of lipid:protein was 100:1.

 PEG-MGDF used in these experiments mono-pegylated (20kDa) *E. coli* derived MGDF 1-163 using mono-
25 methoxy-polyethylene glycol aldehyde (MePEG) (average molecular weight 20 kDa) via reductive alkylation. The homogeneity of the PEG-MGDF conjugates was determined by Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis using 4-20% precast gradient gels
30 (NOVEX). One major band corresponding to the position of a 46.9 kDa protein was revealed.

 DMPG:PEG-MGDF (100:1 mole/mole) samples were then prepared using procedures described above. The DMPG:PEG-MGDF samples were found to fully recover
35 secondary structure after heating (FIGURE 27). Despite the presence of the PEG molecules, the derivatized

-44-

protein was able interact with the lipid in the same way as the native protein.

This data shows that the emission maxima shifts associated with MGDF interaction with a negatively charged lipid vesicle is not unique only to MGDF obtained as a product of procaryotic host cell expression. As was demonstrated with chemically modified rhG-CSF, DMPG:PEG-MGDF also exhibited emission shifts and the data show that chemically modified MGDF can insert into membranes composed of DMPG.

EXAMPLE 11

In this example, the effect of the DMPG:PEG-MGDF interaction as it relates to the problem of MGDF adsorption to glass vials was evaluated. Around 11 pg/ml of [125 I]-PEG-MGDF was combined with various concentrations of unlabeled PEG-MGDF to achieve the indicated final PEG-MGDF concentrations (see FIGURE 28). Where indicated, DMPG was included in the dilution (see also FIGURE 27). 1 mL of the preparations was placed in 3 cc glass vials (Kimble). The % recovery of PEG-MGDF was assayed by counting the amount of radiolabeled MGDF recoverable from the glass vials after an 18 hour incubation at room temperature. As shown in FIGURE 28, PEG-MGDF adsorbs readily to the glass containers as the concentration of the protein is lowered, and the adsorption is especially high in the range of 0.1-50 μ g/ml. By contrast, DMPG:PEG-MGDF samples show almost no adsorption to glass in the range of 0.1-50 μ g/ml PEG-MGDF.

35

-45-

EXAMPLE 12

In this example, the effect of the DMPG:MGDF 1-163 and DMPG:PEG-MGDF 1-163 interaction as it relates to the biological activity of MGDF 1-163 and PEG-MGDF 1-163 was determined. The MGDF 1-163 was *E. coli* derived, and the lipid:protein ratio was 100:1. Platelet counts from mice treated with 100 µg/kg and 300 µg/kg MGDF, PEG-MGDF, DMPG:MGDF or DMPG:PEG-MGDF were measured and the results are presented in FIGURE 31. The indicated concentration of each form was administered subcutaneously into normal, female Balb/c mice once daily for 8 days. Test bleeds from a small lateral cut in a tail vein were collected 24 hours after the last injection. Blood cell analyses were performed with a Sysmex electronic blood cell analyzer (Baxter Diagnostics, Inc. Irvine, CA). Data are represented as the mean of determinations of 4 animals, +/- standard error of the mean. Other blood cell parameters such as total white blood cell counts or red blood cell counts were not affected by these treatments (data not shown). The results indicate that pegylation of *E. coli* MGDF 1-163 increased the *in vivo* activity of the molecule. More importantly, the studies above demonstrate that insertion into negatively charged lipid bilayers does not adversely affect the biological activity of the various MGDF forms.

A-265B

- 46 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: AMGEN INC.
- (ii) TITLE OF INVENTION: STABLE PROTEIN: PHOSPHOLIPID COMPOSITIONS AND METHODS
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Amgen Inc.
 - (B) STREET: 1840 Dehavilland Drive
 - (C) CITY: Thousand Oaks
 - (D) STATE: California
 - (E) COUNTRY: USA
 - (F) ZIP: 91320-1789
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1342 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 99..621

A-265B

- 47 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CAGGGAGCCA CGCCAGCCAA GACACCCCGG CCAGAATGGA GCTGACTGAA TTGCTCCTCG	60
TGGTCATGCT TCTCCTAACT GCAAGGCTAA CGCTGTCC AGC CCG GCT CCT CCT	113
Ser Pro Ala Pro Pro	
1 5	
GCT TGT GAC CTC CGA GTC CTC AGT AAA CTG CTT CGT GAC TCC CAT GTC	161
Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val	
10 15 20	
CTT CAC AGC AGA CTG AGC CAG TGC CCA GAG GTT CAC CCT TTG CCT ACA	209
Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val His Pro Leu Pro Thr	
25 30 35	
CCT GTC CTG CTG CCT GCT GTG GAC TTT AGC TTG GGA GAA TGG AAA ACC	257
Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr	
40 45 50	
CAG ATG GAG GAG ACC AAG GCA CAG GAC ATT CTG GGA GCA GTG ACC CTT	305
Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Leu Gly Ala Val Thr Leu	
55 60 65	
CTG CTG GAG GGA GTG ATG GCA GCA CGG GGA CAA CTG GGA CCC ACT TGC	353
Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gln Leu Gly Pro Thr Cys	
70 75 80 85	
CTC TCA TCC CTC CTG GGG CAG CTT TCT GGA CAG GTC CGT CTC CTC CTT	401
Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln Val Arg Leu Leu Leu	
90 95 100	
GGG GCC CTG CAG AGC CTC CTT GGA ACC CAG CTT CCT CCA CAG GGC AGG	449
Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu Pro Pro Gln Gly Arg	
105 110 115	
ACC ACA GCT CAC AAG GAT CCC AAT GCC ATC TTC CTG AGC TTC CAA CAC	497
Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe Leu Ser Phe Gln His	
120 125 130	
CTG CTC CGA GGA AAG GTG CGT TTC CTG ATG CTT GTA GGA GGG TCC ACC	545
Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr	
135 140 145	
CTC TGC GTC AGG CGG GCC CCA CCC ACC ACA GCT GTC CCC AGC AGA ACC	593
Leu Cys Val Arg Arg Ala Pro Pro Thr Thr Ala Val Pro Ser Arg Thr	
150 155 160 165	
TCT CTA GTC CTC ACA CTG AAC GAG CTC C CAAACAGGAC TTCTGGATTG	641
Ser Leu Val Leu Thr Leu Asn Glu Leu	
170	
TTGGAGACAA ACTTCACTGC CTCAGCCAGA ACTACTGGCT CTGGGCTTCT GAAGTGGCAG	701
CAGGGATTCA GAGCCAAGAT TCCTGGTCTG CTGAACCAA CCTCCAGGTC CCTGGACCAA	761
ATCCCCGGAT ACCTGAACAG GATACACGAA CTCTTGAATG GAACTCGTGG ACTCTTTCTT	821

A-265B

- 48 -

```

GGACCCTCAC GCAGGACCCT AGGAGCCCCG GACATTTTCCT CAGGAACATC AGACACAGGC      881
TCCCTGCCAC CCAACCTCCA GCCTGGATAT TCTCCTTCCC CAACCCATCC TCCTACTGGA      941
CAGTATACGC TCTTCCCTCT TCCACCCACC TTGCCCACCC CTGTGGTCCA GCTCCACCCC     1001
CTGCTTCCTG ACCCTTCTGC TCCAACGCCC ACCCCTACCA GCCCTCTTCT AAACACATCC     1061
TACACCCACT CCCAGAATCT GTCTCAGGAA GGGTAAGGTT CTCAGACACT GCCGACATCA     1121
GCATTGTCTC GTGTACAGCT CCCTTCCCTG CAGGGCGCCC CTGGGAGACA ACTGGACAAG     1181
ATTTCCCTACT TTCTCCTGAA ACCCAAAGCC CTGGTAAAAG GGATACACAG GACTGAAAAG     1241
GGAATCATTT TTCCTGTAC ATTATAAACC TTCAGAAGCT ATTTTTTTTAA GCTATCAGCA     1301
ATACTCATCA GAGCAGCTAG CTCTTTGGTC TATTTTCTGC A                          1342

```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 174 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu
 1           5           10           15
Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gln Cys Pro Glu Val
          20           25           30
His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu
          35           40           45
Gly Glu Trp Lys Thr Gln Met Glu Glu Thr Lys Ala Gln Asp Ile Leu
          50           55           60
Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gln
          65           70           75           80
Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gln Leu Ser Gly Gln
          85           90           95
Val Arg Leu Leu Leu Gly Ala Leu Gln Ser Leu Leu Gly Thr Gln Leu
          100          105          110
Pro Pro Gln Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala Ile Phe
          115          120          125
Leu Ser Phe Gln His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu
          130          135          140

```

A-265B

- 49 -

Val Gly Gly Ser Thr Leu Cys Val Arg Arg Ala Pro Pro Thr Thr Ala
145 150 155 160

Val Pro Ser Arg Thr Ser Leu Val Leu Thr Leu Asn Glu Leu
165 170

WHAT IS CLAIMED IS:

1. A composition comprising a protein capable
5 of transitioning into the molten globular state mixed
with an intact phospholipid liposome vesicle, said
liposome vesicle composed of negatively charged
phospholipids, to form a liposome-protein complex
wherein only a portion of the protein is inserted into
10 the lipid portion of the liposome vesicle.

2. The composition of Claim 1 wherein said
composition has a pH of 3.0 - 7.5 and has at least a
10:1 ratio of lipid:protein.

15 3. The composition of Claim 1 wherein said
liposome vesicle is selected from the group consisting
of dioleoylphosphatidylglycerol (DOPG),
dimyristoylphosphatidylglycerol (DMPG),
20 dipalmitoylphosphatidylglycerol (DPPG),
eggphosphatidylglycerol,
dioleoylphosphatidylethanolamine (DOPE),
eggphosphatidylethanolamine, dioleoylphosphatidic acid
(DOPA), dimyristoylphosphatidic acid (DMPA),
25 dipalmitoylphosphatidic acid (DPPA),
dioleoylphosphatidylserine (DOPS),
dimyristoylphosphatidylserine (DMPS),
dipalmitoylphosphatidylserine (DPPS),
eggphosphatidylserine, lysophosphatidylglycerol,
30 lysophosphatidylethanolamine, and
lysophosphatidylserine.

4. The composition of Claim 1 wherein said
protein is a cytokine.

35

5. The composition of Claim 4 wherein said cytokine is a hematopoietic factor.

5 6. The composition of Claim 5 wherein said hematopoietic factor is selected from the group consisting of G-CSF, GM-CSF and MGDF.

7. The composition of Claim 6 wherein said hematopoietic factor is G-CSF.

10

8. The composition of Claim 7 wherein the G-CSF is natural human G-CSF or is obtained as a product of procaryotic or eukaryotic host cell expression.

15

9. The composition of Claim 7 wherein the G-CSF is chemically modified G-CSF.

10. The composition of Claim 9 wherein the chemically modified G-CSF is pegylated G-CSF.

20

11. The composition of Claim 6 wherein said hematopoietic factor is MGDF.

12. The composition of Claim 11 wherein the MGDF is natural human MGDF or is obtained as a product of procaryotic or eukaryotic host cell expression.

25

13. The composition of Claim 12 wherein the MGDF has an amino acid sequence of:

30

MGDF 1-163 amino acids 1-163 of FIGURE 29.

14. The composition of Claim 12 wherein the MGDF has an amino acid sequence of:

35

MGDF 1-332 amino acids 1-332 of FIGURE 29.

15. The composition of Claim 11 wherein the MGDF is chemically modified MGDF.

16. The composition of Claim 15 wherein the
5 chemically modified MGDF is pegylated MGDF (PEG-MGDF).

17. The composition of Claim 16 wherein the PEG-MGDF is pegylated with polyethylene glycol.

18. The composition of Claim 17 wherein the
10 PEG-MGDF is mono-pegylated MGDF (mPEG-MGDF).

19. The composition of Claim 18 wherein the PEG group is attached to the N-terminus thereof.
15

20. The composition of Claim 1 wherein said composition contains a pharmaceutically acceptable carrier.

21. The composition of Claim 1 wherein said
20 protein is *E. coli* derived rhG-CSF, wherein said liposome vesicle is DOPG, and wherein said composition has a 50:1 ratio of DOPG:rhG-CSF, has a pH of 4.5 and contains 10 mM sodium acetate.

22. The composition of Claim 1 wherein said
25 protein is *E. coli* derived MGDF 1-163, wherein said liposome vesicle is DMPG, and wherein said composition has a 100:1 ratio of DMPG:MGDF, has a pH of 5.0 and
30 contains 10 mM sodium acetate, 5% sorbitol.

23. The composition of Claim 1 wherein said
protein is mono-pegylated *E. coli* derived MGDF (mPEG-MGDF), wherein said liposome vesicle is DMPG, and
35 wherein said composition has a 100:1 ratio of DMPG:mPEG-

MGDF, has a pH of 5.0 and contains 10 mM sodium acetate, 5% sorbitol.

24. The composition of Claim 1 wherein said
5 protein is CHO derived MGDF 1-332, wherein said liposome vesicle is DMPG, and wherein said composition has a 100:1 ratio of DMPG:MGDF, has a pH of 5.0 and contains 10 mM sodium acetate, 5% sorbitol.

10 25. A method of preparing a liposome-protein composition comprising mixing a protein, wherein said protein is capable of transitioning into the molten globular state, with an intact phospholipid liposome vesicle, wherein said liposome vesicle is negatively
15 charged, such that only a portion of said protein is inserted into the lipid portion of said liposome vesicle, and obtaining said liposome-protein composition.

20 26. A method according to Claim 25 wherein said composition has a pH of 3.0 - 7.5 and has at least a 10:1 ratio of lipid:protein.

27. A method according to Claim 25 wherein
25 said liposome vesicle is prepared from a lipid selected from the group consisting of dioleoylphosphatidylglycerol (DOPG), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG),
30 eggphosphatidylglycerol, dioleoylphosphatidylethanolamine (DOPE), eggphosphatidylethanolamine, dioleoylphosphatidic acid (DOPA), dimyristoylphosphatidic acid (DMPA), dipalmitoylphosphatidic acid (DPPA),
35 dioleoylphosphatidylserine (DOPS), dimyristoylphosphatidylserine (DMPS),

dipalmitoylphosphatidylserine (DPPS),
eggphosphatidylserine, lysophosphatidylglycerol,
lysophosphatidylethanolamine, and
lysophosphatidylserine.

5

28. A method according to Claim 25 wherein
said protein is a cytokine.

29. A method according to Claim 28 wherein
10 said cytokine is a hematopoietic factor.

30. A method according to Claim 29 wherein
said hematopoietic factor is selected from the group
consisting of G-CSF, GM-CSF and MGDF.

15

31. A method according to Claim 30 wherein
said hematopoietic factor is G-CSF.

32. A method according to Claim 31 wherein the
20 G-CSF is natural human G-CSF or is obtained as a product
of procaryotic or eukaryotic host cell expression.

33. A method according to Claim 31 wherein the
G-CSF is chemically modified G-CSF.

25

34. A method according to Claim 33 wherein the
chemically modified G-CSF is pegylated G-CSF.

35. A method according to Claim 30 wherein
30 said hematopoietic factor is MGDF.

36. A method according to Claim 35 wherein
the MGDF is natural human MGDF or is obtained as a
product of procaryotic or eukaryotic host cell
35 expression.

37. A method according to Claim 36 wherein the MGDF has an amino acid sequence of:

MGDF 1-163 amino acids 1-163 of FIGURE 29.

5 38. A method according to Claim 36 wherein the MGDF has an amino acid sequence of:

MGDF 1-332 amino acids 1-332 of FIGURE 29.

10 39. A method according to Claim 35 wherein the MGDF is chemically modified MGDF.

40. A method according to Claim 39 wherein the chemically modified MGDF is pegylated MGDF (PEG-MGDF).

15 41. A method according to Claim 40 wherein the PEG-MGDF is pegylated with polyethylene glycol.

42. A method according to Claim 41 wherein the PEG-MGDF is mono-pegylated MGDF (mPEG-MGDF).

20 43. A method according to Claim 42 wherein the PEG group is attached to the N-terminus thereof.

44. A method according to Claim 25 wherein said composition contains a pharmaceutically acceptable carrier.

30 45. A method according to Claim 21 wherein said inserting includes insertion of a portion of said protein into a lipid bilayer of said lipid vesicle.

46. A method according to Claim 21 wherein said liposome-protein composition is directly stabilized against unfolding of the secondary structure of said protein.

35




FIG. 2A




FIG. 2B




FIG. 3





FIG. 4



6/35

FIG.5




FIG. 6





FIG. 7



9/35




FIG. 9





FIG. 10



12/35

FIG. II




FIG. 12





FIG. 13



15/35

FIG. 14






FIG. 15




- G-CSF
- DOPA:G-CSF (50:1)
- DMPA:G-CSF (50:1)

FIG. 16



18/35

FIG.17



SUBSTITUTE SHEET (RULE 26)

FIG. 18




FIG. 19A





FIG. 19B



22/35

FIG. 20A




FIG. 20B




FIG. 21




FIG. 22




FIG. 23






FIG. 24



○ MDGF

DMPG:MGDF (100:1)

FIG. 25



29/35

FIG. 26




FIG. 27




FIG. 28




FIG. 29A

1	CAGGGAGCCACGCCAGCCAAGACACCCCGCCAGAAATGGAGCTGACTGAATTGCTCCTC	53
-21	MetGluLeuThrGluLeuLeuLeu	-14
70	GTGGTCATGCTTCTCCTAACTGCAAGGCTAACGCTGTCCAGCCCGGCTCCTCCTGTTGT	119
-13	ValValMetLeuLeuLeuThrAlaArgLeuThrLeuSerSerProAlaProProAlaCys	7
120	GACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCTTTCACAGCAGACTGAGC	179
8	AspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSer	27
180	CAGTGCCCCAGAGGTTACCCCTTTGCCTACACCTGTCTGCTGCTGCTGTGGACTTTAGC	239
28	GlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSer	47
240	TTGGGAGATGGAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTG	299
48	LeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaVal	67
300	ACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACCTGGGACCCACTTGCCTCTCA	359
68	ThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSer	87
360	TCCCTCCTGGGCGAGCTTCTTGACAGGTCCGCTCTCCTCCTTGGGGCCCTGCAGAGCCTC	419
88	SerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeu	107
420	CTTGGAACCCAGCTTCCCTCACAGGGCAGGACCACAGCTCACAAAGGATCCCAATGCCATCC	479
108	LeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlaIle	127
480	TTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGTGCGTTTCTCTGATGCTTGTAGGAGGG	539
128	PheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGly	147
540	TCCACCCCTCTGCGTCAGGGGGGGCCCCACCCACACAGCTGTCCCCCAGCAGAACCCTCTTA	599
148	SerThrLeuCysValArgArgAlaProProThrThrAlaValProSerArgThrSerLeu	167

32/35

FIG. 29B

600	GTCTCACA	659
168	ValLeuThrLeuAsnGluLeuProAsnArgThrSerGlyLeuLeuGluThrAsnPheThr	187
660	GCCTCAGCCAGAACTACTGGCTCTGGGCTTCTGAAGTGCAGCAGGATTCAGAGCCCAAG	719
188	AlaSerAlaArgThrThrGlySerGlyLeuLeuLysTrpGlnGlnGlyPheArgAlaLys	207
720	ATTCTTGGTCTGTGAACCAACCTCCAGTCCCTGGACCAAAATCCCCGGATACCTGAAC	779
208	IleProGlyLeuLeuAsnGlnThrSerArgSerLeuAspGlnIleProGlyTyrLeuAsn	227
780	AGGATACACGAACTCTTGAATGGAACTCGTGGACTCTTCTCTGGACCCCTCACGCGAGGACC	839
228	ArgIleHisGluLeuLeuAsnGlyThrArgGlyLeuPheProGlyProSerArgArgThr	247
840	CTAGGAGCCCCGGACATTTCTCTCAGGAACATCAGACACAGGCTCCCTGCCACCCAAACCTC	899
248	LeuGlyAlaProAspIleSerSerGlyThrSerAspThrGlySerLeuProProAsnLeu	267
900	CAGCCTGGATATTCTCTTCCCCAACCCATCCTCTACTGGACAGTATACGCTCTTCCCT	959
268	GlnProGlyTyrSerProSerProThrHisProProThrGlyGlnTyrThrLeuPhePro	287
960	CTTCCACCCACCTTGCCCCACCCCTGTGGTCCAGCTCCACCCCTGCTTCTTGACCCCTTCT	1019
288	LeuProProThrLeuProThrProValValGlnLeuHisProLeuLeuProAspProSer	307
1020	GCTCCAACGCCCAACCCCTACAGCCCTCTTCTAAACACATCCTACACCCACTCCCAGAAAT	1079
308	AlaProThrProThrProThrSerProLeuLeuAsnThrSerTyrThrHisSerGlnAsn	327
1080	CTGTCTCAGGAAGGTAAGGTTCTCAGACACTGCCGACATCAGCATTTGTCTCGTGTACAG	1139
329	LeuSerGlnGluGlyEnd	
1140	CTCCCTTCCCTGCAGGGGCCCCCTGGGAGACAACTGGACAAAGATTTCTTCTCCTG	1199
1200	AAACCCAAAGCCCTGGTAAAGGGATACACAGGACTGAAAAGGGAATCATTTTCACTGT	1259
1260	ACATTATAAACCTTCAGAAGCTATTTTTTAAAGCTATCAGCAATACTCATCAGAGCAGCT	1319
1320	AGCTCTTTGGTCTATTTTCTGCA	1342

FIG. 30





FIG. 31



INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 96/04261

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K9/127 A61K38/19

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X, L	WO,A,95 09611 (AMGEN INC.) 13 April 1995 the priority claim of the present application might not be justified. see the whole document ---	1-10,21, 25-34, 44-46
A	PATENT ABSTRACTS OF JAPAN vol. 016, no. 298 (C-0958), 2 July 1992 & JP,A,04 082839 (GREEN CROSS CORP), 16 March 1992, see abstract ---	1-46
A	EP,A,0 422 543 (THE GREEN CROSS CORPORATION) 17 April 1991 see page 3 - page 4; example 2 --- -/--	1-46

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

12 August 1996

Date of mailing of the international search report

20.08.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Benz, K

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/04261

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>EP,A,0 393 707 (OTSUKA PHARMACEUTICAL CO., LTD.) 24 October 1990 see the whole document see page 5, line 58 - page 6, line 4 -----</p>	1-46

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 96/04261

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9509611	13-04-95	AU-B- 7923994	01-05-95
		CA-A- 2150939	13-04-95
		CN-A- 1117266	21-02-96
		CZ-A- 9501438	17-01-96
		EP-A- 0671905	20-09-95
		FI-A- 952738	31-07-95
		HU-A- 72326	29-04-96
		JP-T- 8505403	11-06-96
		NO-A- 952210	04-08-95
		ZA-A- 9407782	17-05-95
EP-A-422543	17-04-91	JP-A- 3127622	30-05-91
EP-A-393707	24-10-90	DE-D- 69013557	01-12-94
		JP-A- 3034920	14-02-91
		KR-B- 9404390	25-05-94

